Stem cell therapy takes advantage of the special healing quality of stem cells. These cells can help repair damaged tissues in the body. Stem cells are found in your bone marrow. The Sports Medicine physicians at The Orthopaedic Center specialize in both BMAC and PRP treatments.
Bone Marrow Aspirate Concentrate (BMAC) treatment, also known as Bone Marrow Concentrate (BMC) treatment is a non-surgical regenerative treatment for various orthopedic injuries, including moderate to severe osteoarthritis and tendon injures. BMAC is a concentrate of regenerative stem cells obtained from the patients own bone marrow. The physician removes a small amount of the patients bone marrow and uses it to generate a powerful concentrate that is injected into the treatment area.
Unlike other cells of the body, bone marrow cells are undifferentiated, which means they have the ability to transform themselves into a variety of tissue types. When injury occurs, the quantity of regenerative cells needed for tissue regeneration may be inadequate. With BMAC, the injection of regenerative cells provides a more robust healing of damaged tissue and aids in growth and repair by accelerating the bodys natural healing mechanism. While the full benefits of BMAC are still unknown, BMAC has been shown to reduce swelling, relieve pain, and enhance healing of articular cartilage and bone.
Numerous conditions can be considered for treatment with BMAC. Currently, moderate to severe osteoarthritis and severe tendon injuries show promising results.
Knee Osteoarthritis is currently the best indication. Others are listed below.
In general, PRP may be more appropriate for mild to moderate osteoarthritis or tendon injuries. BMAC may be reserved for more challenging cases such as moderate to severe osteoarthritis or when more potent effects are desired.
With the patient sedated, the bone marrow aspiration site is locally numbed so minimal pain is felt. Bone marrow is removed from the back of the pelvis (hip) at the posterior iliac crest. The concentration of bone marrow (stem cells and healing components), also known as the bone marrow aspirate concentrate (BMAC), is injected into the treatment area. Patients go home the same day.
Unlike cortisone/steroid shots which simply mask symptoms (and may damage tissue with repeated injections), BMAC targets the root of the problem and attempts to heal the tissue.
Most patients require only a single BMAC treatment. However, if a patient experiences significant relief that plateaus, they may consider a second BMAC injection months later.
For the first 2-3 days, swelling and discomfort may occur in the injected area. By the end of the first week, these symptoms usually begin to resolve. Physical therapy is started within a few days of the treatment, to optimize BMAC effects and facilitate recovery. Patients respond to BMAC treatment along varying timelines.
Bone marrow derived cancer (such as lymphoma) and active systemic infection are contra-indications. Other types of cancer may be a contra-indication and approval must be obtained from the patients oncologist.
No. While there is evidence showing the positive effects of BMAC treatment on tendon, soft tissue, and cartilage injuries, BMAC is not covered by insurance companies at this time.
Most patients notice some level of improvement by 2-6 weeks following their BMAC treatment. Increases in stability and strength are typically reported, along with the decreases in pain. A second level of benefit may be obtained between 6 weeks and 3 months following BMAC. Patients should remain active with a physical therapy program and strengthen surrounding muscles during this period.
Platelet-Rich Plasma (PRP) is produced from your own blood. Platelets are cells in our body that contain growth factors. These growth factors stimulate the normal wound healing process, such as when your skin heals after a scrape. For PRP treatments, we concentrate your platelets (to over 5x more platelets than your normal blood) and deliver them to the area of interest, to help heal injured tissue. Some PRP treatments are done under ultrasound guidance to confirm placement of the PRP in the correct tissue.
PRP is indicated for injuries that have failed to heal despite traditional treatments. PRP treatments can be performed in any musculoskeletal structure, including muscles, tendons, joints and ligaments. Some examples include: partial tendon tears, muscle strains, ligament sprains/partial tears, articular cartilage injury, and chronic tendon injuries.
To prepare PRP, blood is taken from your arm with a special kit. This is similar to a normal blood draw. The blood is then placed in a centrifuge that separates the platelets from the blood, creating the PRP. The entire PRP treatment process takes about 45 minutes.
Many patients achieve successful outcomes with only one treatment, especially for soft-tissue problems. In some cases, a series of three treatments is required to achieve significant results. This is particularly true for joint treatments. Each treatment is spaced several weeks apart. There is no limit to the number of treatments you can have; however, if youre not seeing significant improvement after three treatments, you should consider other forms of treatment.
Since your own blood is used, there is no risk for transmitted blood-infections. PRP has a strong antibacterial effect so the risk of local infection is minimal. It is possible to have increased soreness or pain for several days after the treatment. You may be prescribed pain medication to help with this.
PRP treatment is a fairly new procedure, and most insurance companies have not incorporated it yet to their list of approved procedures and do not consider it a reimbursable expense. PRP treatment fees include the PRP kit, blood draw, use of centrifugation machine, disposable equipment, ultrasound guidance (if needed), and the actual procedure. A splint for support may be indicated in some cases (additional fee, likely with some insurance coverage).
PRP stimulates healing of the injured tissue by activating your bodys natural healing potential. On average, patients report more than 50% improvement at 6 weeks and up to 100% improvement at 12 weeks after treatment. PRP treatment may eliminate the need for other treatments such as long-term medication or surgery.
Excerpt from:
Regenerative Medicine | Stem Cell Therapy | Huntsville AL
- Navigating the hope and hype of regenerative medicine - October 14th, 2024
- Cell and Gene Therapy Investment Ticks Up After Hard Few Years - BioSpace - October 14th, 2024
- Crackdowns on Unproven Stem Cell Therapies Worked Abroad - Medpage Today - October 14th, 2024
- How Regenerative Medicine can help you get out of pain without surgery - WJLA - October 14th, 2024
- Regenity Biosciences Receives 510(k) Clearance for RejuvaKnee, a Groundbreaking Regenerative Meniscus Implant Device to Redefine the Standard of Care... - October 14th, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - BioPharm International - October 14th, 2024
- Mayo Clinic offers unique regenerative medicine procedure for knee and ... - September 13th, 2024
- Regenerative Medicine to the Rescue - Cleveland Clinic - September 13th, 2024
- Regenerative medicine applications: An overview of clinical trials - September 13th, 2024
- The Progression of Regenerative Medicine and its Impact on Therapy ... - September 13th, 2024
- Immune cell injection significantly boosts healing of bone, muscle & skin - September 13th, 2024
- Regenerative Medicine Foundation - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT ... - September 13th, 2024
- Tissue engineering and regenerative medicine approaches in colorectal ... - September 13th, 2024
- Tubular scaffolds boost stem cell-driven bone regeneration in skull defects - Phys.org - September 13th, 2024
- Finding the right path(way) to reduce fat accumulation in the liver - Medical University of South Carolina - September 13th, 2024
- NAMRU EURAFCENT Signs Agreement with Egypt Center for Research and Regenerative Medicine - DVIDS - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program - StockTitan - September 13th, 2024
- BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and... - September 13th, 2024
- Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate - Yahoo Finance - September 13th, 2024
- Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets - Nature.com - September 13th, 2024
- Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H) - Business Wire - September 13th, 2024
- HepaTx Enters Collaboration with Mayo Clinic to Advance Cell Therapy Technology for Liver Disease to Clinical Trials - Longview News-Journal - September 13th, 2024
- Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma -... - September 4th, 2024
- Regenerative Medicine in Orthopedic Surgery: Expanding Our Toolbox - Cureus - September 4th, 2024
- Somite.ai takes pre-seed to $10M as it eyes to become the OpenAI of stem cell biology - CTech - September 4th, 2024
- Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) - Yahoo... - September 4th, 2024
- Study Explores Potential Of 3D Printed Regenerative Breast Implants - Forbes - September 4th, 2024
- Nikon Announces New Image Analysis Functions to Empower Drug Discovery Research for Cancer, Neurological Disease, and Regenerative Medicine - PR... - September 4th, 2024
- Trinity researcher scores 800,000 to boost regenerative medicine - SiliconRepublic.com - September 4th, 2024
- Seeing the future: Zebrafish regenerates fully functional photoreceptor cells and restores its vision - EurekAlert - September 4th, 2024
- Regenerative Medicine Industry Projected to Surge to USD 73,084.2 Million by 2033, Growing at an 18.5% CAGR - Future Market Insights - September 4th, 2024
- What is regenerative medicine? | Northwell Health - July 2nd, 2024
- Science Saturday: A regenerative reset for aging - July 2nd, 2024
- Science Saturday: A year of new directions and advancements for ... - March 29th, 2024
- Diverse ways regenerative medicine is advancing health care - March 29th, 2024
- Stem cell-based regenerative medicine - PMC - National Center for ... - February 27th, 2024
- Regenerative medicine | NIST - February 10th, 2024
- San Jose blood stem cell donor meets 15-year-old whose life he saved in Los Angeles - The Mercury News - May 17th, 2023
- Regenerative medicine: Current therapies and future directions - April 23rd, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - April 23rd, 2023
- Important Patient and Consumer Information About Regenerative Medicine ... - April 23rd, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 23rd, 2023
- About Regenerative Medicine - Center for Regenerative ... - Mayo Clinic - April 7th, 2023
- Regenerative Medicine | National Institutes of Health (NIH) - April 7th, 2023
- Porcine Vaccine Market is estimated to be US$ 4.41 billion by 2030 with a CAGR of 7.50%during the forecast - EIN News - April 7th, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 21st, 2023
- Active Wound Care Market Rising demand for Skin Substitutes to boost the industry (2023-2033) | CAGR of 5.5% - EIN News - March 21st, 2023
- Veterinary Orthopedic Implants Market is estimated to be 421.3 Million by 2029 with a CAGR of 5.3% - By PMI - EIN News - March 21st, 2023
- ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical VHH to address an unmet medical... - February 8th, 2023
- A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field - Yahoo Finance - October 15th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 15th, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 15th, 2022
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 15th, 2022
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 15th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - GlobeNewswire - October 15th, 2022
- Discover Medical Advances in Cellular Therapy Research Using Cord Blood for Cancer, HIV, Cerebral Palsy and Autism During World Cord Blood Day 2022 -... - October 15th, 2022
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 15th, 2022
- Cell therapy weekly: Ray Therapeutics and Forge Biologics expand partnership - RegMedNet - October 15th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 15th, 2022
- Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Business Wire - October 15th, 2022
- The Health Benefits Of Sea Moss, According To Experts - Forbes - October 15th, 2022
- ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of ... - The Bakersfield Californian - October 15th, 2022
- Pain Management & Regenerative Medicine Specialists DFW - September 4th, 2022
- Tissue Engineering and Regenerative Medicine - National Institute of ... - September 4th, 2022
- First U.S. patient receives autologous stem cell therapy to treat dry AMD - National Institutes of Health (.gov) - September 4th, 2022
- International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt - Construction Review - September 4th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - September 4th, 2022
- Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic - BioSpace - September 4th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 4th, 2022
- TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all... - September 4th, 2022
- Frequency Therapeutics to Participate in September Investor and Medical Conferences - Business Wire - September 4th, 2022
- Can the immortal jellyfish teach us how to reverse aging? - Earth.com - September 4th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - September 4th, 2022
- Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - PR Newswire - September 4th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 4th, 2022
- Regenerative Medicine Partnering 2015 to 2022: Terms and Agreements Entered Into by the Leading Companies Worldwide - ResearchAndMarkets.com -... - August 19th, 2022
- Pain Relief Treatments: The Benefits of Regenerative Medicine From Head to Toe - 30Seconds.com - August 19th, 2022
- FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products - Wilson Sonsini Goodrich... - August 19th, 2022
- Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert - August 19th, 2022